RPG Life Sciences Limited has announced its financial results for the third quarter ended 31 December, 2025.
| Q3 FY26 Highlights | Q-o-Q Revenue from operations |
| Rs. 180.0 crores vs. Rs. 181.7 crores |
| Q3 FY26 Highlights | Y-o-Y Revenue from operations |
| Rs. 180.0 crores vs. Rs. 172.7 crores | |
| 9M FY26 Highlights | Rs. 530.6 crores vs. Rs. 510.3 crores |
In Q3 FY26, RPG Life Sciences recorded a 4.2% Y-o-Y increase in revenue, along with a healthy EBITDA margin of 24.0%. For 9M FY26, revenue grew 4.0% Y-o-Y, maintaining operational momentum.
Commenting on the results and the business outlook, Mr. Ashok Nair, Managing Director, RPG Life Sciences Ltd., said, “Q3 reflects continued traction across our core businesses supported by disciplined execution and deliberate portfolio actions. Our Domestic Formulations business delivered growth ahead of the Indian Pharmaceutical Market, recording a growth of 11.8% in 9M FY26 compared to the IPM growth of 8.2%, driven by strong brand performance, improved field effectiveness, and sharper customer engagement. Our approach remains firmly rooted in quality and improving patient outcomes.”
“Looking ahead, we remain committed to building a future-ready pharmaceutical enterprise — one that is resilient, innovation-led, and people-first, creating sustainable value for patients, partners, and stakeholders,” added Nair.
